GlassScriptPhysician profile
Omid Heravi
NPI 1821523044
$6,499.84
in general payments reported to CMS, 2019-2025
45 companies · $138 in 2025
The $138 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.68 · 2022: $855 · 2023: $2,601 · 2024: $2,823 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,153 · Education: $711 · Long Term Medical Supply Or Device Loan: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,153.04 |
| Education | $710.85 |
| Long Term Medical Supply Or Device Loan | $697.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $742.42 | 2024-2025 | |
| Janssen Biotech, INC. | $501.51 | 2022-2024 | Tecvayli, Darzalex, Talvey |
| Genzyme Corporation | $475.19 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $474.75 | 2023-2024 | Andexxa, Tagrisso, Enhertu |
| Alexion Pharmaceuticals, INC. | $316.58 | 2023-2024 | Ultomiris, Soliris |
| Seagen INC. | $307.92 | 2023 | Tukysa, Adcetris, Padcev |
| Incyte Corporation | $298.54 | 2022-2024 | Jakafi |
| Gilead Sciences, INC. | $279.58 | 2022-2025 | Trodelvy |
| Pfizer INC. | $218.39 | 2021-2024 | |
| Emd Serono, INC. | $210.87 | 2022-2024 | Tepmetko |
| Eisai INC. | $205.47 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $203.11 | 2022-2024 | Libtayo |
| Merck Sharp & Dohme LLC | $200.04 | 2021-2024 | Keytruda, Welireg, Lynparza |
| Octapharma USA, INC. | $184.73 | 2023-2024 | Panzyga, Balfaxar, Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Takeda Pharmaceuticals U.S.A., INC. | $176.34 | 2023-2024 | Ninlaro, Iclusig |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omid Heravi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.